Source comparison
Tesamorelin + Ipamorelin Blend Gene Expression: Peptide Comparison
Before selecting a peptide protocol, understanding how different compounds alter gene transcription helps researchers design experiments that target specific molecular outcomes. Tesamorelin alone GHRH receptor (anterior pituitary) GH1, IGF-1 upregulation withi
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, understanding how different compounds alter gene transcription helps researchers design experiments that target specific molecular outcomes.
- Tesamorelin alone
- GHRH receptor (anterior pituitary)
- GH1, IGF-1 upregulation within 2–4 hours
- Moderate PGC-1α increase (1.4–1.9-fold)
- Strong SREBP-1c suppression, moderate ATGL upregulation
- Best for direct growth hormone synthesis research; limited mitochondrial effect without combination
- Ipamorelin alone
- GHS-R1a (ghrelin receptor)
- Pulsatile GH release, AMPK pathway activation
- Mild PGC-1α increase (1.2–1.5-fold), enhanced TFAM expression
- Moderate HSL upregulation, insulin sensitivity gene improvement
- Superior for studying pulsatile secretion patterns; weaker standalone lipolytic transcription
- Tesamorelin + Ipamorelin blend
- Dual pathway (GHRH + GHS-R1a)
- Sustained GH1/IGF-1 elevation + AMPK-dependent gene networks
- Robust PGC-1α increase (2.1–2.8-fold), NRF1/NRF2/TFAM upregulation
- Combined SREBP-1c suppression + ATGL/HSL upregulation, enhanced CPT1A expression
- Optimal for comprehensive metabolic gene expression studies; non-redundant pathways produce additive transcriptional effects
- CJC-1295 + Ipamorelin
- Modified GHRH analog + GHS-R1a
- Prolonged half-life extends gene expression window by 48–72 hours
- Similar PGC-1α effect but sustained longer due to CJC-1295 half-life
- Comparable lipolytic gene changes with extended duration
- Alternative for protocols requiring less frequent dosing; gene expression timeline differs from tesamorelin